drugset / Trial / NCT04209933
Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to compare efficacy and safety of bismuth-containing quadruple therapy(with rabeprazole amoxicillin clarithromycin)of different kinds of bismuth(Bismuth potassium citrate, pectin bismuth capsules, pectin bismuth particles)in H. pylori first-line eradication. It is hypothesized that different bismuth containing quadruple therapies have comparable eradication efficacy and safety. Patients with confirmed H. pylori positive status will be randomized to one of the treatments described above. At week 2and 6 follow-up visits, a urea breath test(UBT) will be performed to confirm eradication.
Timeline
- Start
- 2020-05-25
- Primary completion
- 2020-08-01
- Completion
- 2020-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bismuth Potassium Citrate | Unknown | 220 mg | Oral |
| Comparator | Colloidal pectin bismuth | Unknown | 200 mg | Oral |
| Comparator | Colloidal pectin bismuth particles | Unknown | 150 mg | Oral |
| Comparator | Colloidal pectin bismuth particles | Unknown | 300 mg | Oral |
| Comparator | Amoxicillin | Other / unclassified | 1000 mg | Oral |
| Comparator | Clarithromycin | Small molecule | 500 mg | Oral |
| Comparator | Rabeprazole | Small molecule | 10 mg | Oral |